# Are Diabetics Clinically Vulnerable? A Comprehensive Analysis

## Introduction

The COVID-19 pandemic has brought significant attention to the vulnerability of various populations, especially those with underlying health conditions such as diabetes. Diabetes mellitus, a chronic metabolic disorder characterized by hyperglycemia, affects millions globally and poses complex challenges in the context of infectious diseases. This report aims to provide a detailed, evidence-based analysis of whether individuals with diabetes are clinically vulnerable, particularly in relation to COVID-19, but also considering broader health implications. The analysis synthesizes data from authoritative sources, including Diabetes UK, peer-reviewed clinical studies, and epidemiological reviews, to present a nuanced understanding of the risks, clinical outcomes, and public health considerations for diabetics.

## Defining Clinical Vulnerability in Diabetes

Clinical vulnerability refers to an increased risk of adverse health outcomes, including severe illness or death, when exposed to specific health threats such as infections. In the context of COVID-19, the UK Government classifies people with diabetes as "clinically vulnerable," implying a moderate risk of becoming seriously ill if infected ([Diabetes UK, 2020](https://www.diabetes.org.uk/about_us/news/coronavirus-new-guidance-response)).

However, distinctions exist between "clinically vulnerable" and "clinically extremely vulnerable" (CEV) groups. The latter includes individuals with conditions conferring the highest risk, such as those on dialysis or with stage 5 chronic kidney disease. Notably, many people with diabetes, even those with additional risk factors like age, obesity, ethnicity, or poor glycemic control, have not consistently been classified as CEV, raising concerns about adequate protection and support ([Diabetes UK, 2020](https://www.diabetes.org.uk/about_us/news/coronavirus-new-guidance-response)).

## Epidemiological Evidence of Vulnerability

### Prevalence and Risk of Severe COVID-19 Outcomes

Epidemiological studies consistently show that diabetes is a significant comorbidity in patients with COVID-19, associated with increased risk of hospitalization, severe disease, intensive care admission, and mortality.

- Approximately 30–40% of people hospitalized with COVID-19 have type 1 or type 2 diabetes ([Gregg et al., 2021](https://care.diabetesjournals.org/content/44/9/1916)).
- Among hospitalized diabetics, 21–43% require intensive care, and case fatality rates are around 25% ([Gregg et al., 2021](https://care.diabetesjournals.org/content/44/9/1916)).
- The risk of severe morbidity and mortality is 100–250% higher in diabetics compared to non-diabetics, even after adjusting for sociodemographic factors and comorbidities ([Gregg et al., 2021](https://care.diabetesjournals.org/content/44/9/1916)).

### Population-Level Impact

Population-based studies in England and Scotland reveal:

- Odds ratios (ORs) for COVID-19-related death are approximately 3.5 for type 1 diabetes and 2.0 for type 2 diabetes ([Holman et al., 2020](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30271-0/fulltext)).
- Excess mortality during the pandemic was 51% higher in type 1 diabetes and 64% higher in type 2 diabetes compared to historical trends ([Holman et al., 2020](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30271-0/fulltext)).
- Diabetes-related mortality increases were more than twice the impact seen in the general population ([Holman et al., 2020](https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30271-0/fulltext)).

### Risk Factors Within the Diabetic Population

Risk is not uniform among all people with diabetes. Key factors influencing vulnerability include:

| Risk Factor               | Impact on COVID-19 Outcomes                          |
|--------------------------|-----------------------------------------------------|
| Age                      | Older age significantly increases risk              |
| Glycemic Control (HbA1c) | Poor control (HbA1c ≥9.0%) increases mortality risk |
| Comorbidities            | Chronic kidney disease, cardiovascular disease, obesity increase risk |
| Ethnicity                | Black, Asian, and minority ethnic groups have higher risk |
| Sex                      | Male sex associated with increased mortality        |

(Table adapted from Holman et al., 2020; Gregg et al., 2021)

## Clinical Considerations Beyond COVID-19

### Diabetes and Malnutrition

Malnutrition, particularly protein-energy malnutrition, is prevalent among diabetics, especially the elderly, and exacerbates poor health outcomes, including delayed healing and increased risk of infection ([Sallé, 2018](https://www.sciencedirect.com/science/article/pii/S0985056217301942)). Malnutrition increases hospital stay length and mortality risk, compounding vulnerability.

### Diabetic Emergencies in Urgent Care

Diabetic patients are prone to acute glycemic emergencies such as diabetic ketoacidosis (DKA), hyperosmolar hyperglycemic state (HHS), and hypoglycemia, which require immediate medical intervention ([Moore et al., 2008](https://www.jucm.com/diabetic-emergencies-in-the-urgent-care-setting/)). These emergencies can be life-threatening and are more frequent in poorly managed diabetes or in the presence of infections like COVID-19.

## Employment and Social Vulnerability

People with diabetes face challenges in the workplace, especially during the pandemic. While classified as clinically vulnerable, many are not recognized as clinically extremely vulnerable, limiting access to financial support and workplace accommodations ([Diabetes UK, 2020](https://www.diabetes.org.uk/guide-to-diabetes/life-with-diabetes/employment)).

Employers are legally required to conduct risk assessments and make reasonable adjustments under the Equality Act 2010 (England, Scotland, Wales) or Disability Discrimination Act 1995 (Northern Ireland). However, guidance is often insufficiently specific for diabetics, leading to disparities in protection and support.

## Government Guidance and Advocacy

The UK Government’s adoption of the QCovid Population Risk Assessment tool represents progress in identifying individuals at higher risk, including those with diabetes and additional risk factors ([Diabetes UK, 2021](https://www.diabetes.org.uk/about_us/news/1-7-million-extra-people-in-england-asked-to-shield)). This tool enables more individualized risk stratification and prioritization for vaccination and shielding support.

Nonetheless, Diabetes UK and other organizations continue to advocate for broader recognition of risk factors among diabetics and for equitable access to financial and workplace protections.

## Summary and Conclusion

Based on the comprehensive review of current evidence, it is clear that:

- **People with diabetes are clinically vulnerable**, with a substantially increased risk of severe illness and death from COVID-19 compared to non-diabetics.
- The level of vulnerability varies within the diabetic population, influenced by age, glycemic control, comorbidities, ethnicity, and sex.
- Diabetics also face increased risk of malnutrition and acute glycemic emergencies, which compound their clinical vulnerability.
- Existing government guidance in England classifies diabetics as clinically vulnerable but often fails to adequately protect those with additional risk factors, leading to gaps in support and workplace accommodations.
- The introduction of individualized risk assessment tools like QCovid is a positive step but requires wider implementation and recognition across the UK.
- Continued advocacy and research are needed to optimize clinical management, public health policies, and social support for people with diabetes.

In conclusion, diabetics should be regarded as clinically vulnerable, requiring tailored clinical care, public health interventions, and social protections to mitigate their increased risk, especially in the context of infectious diseases like COVID-19.

---

## References

- Diabetes UK. (2020, November 5). *We respond to new government guidance for clinically extremely vulnerable people in England*. Diabetes UK. https://www.diabetes.org.uk/about_us/news/coronavirus-new-guidance-response

- Gregg, E. W., Sophiea, M. K., & Weldegiorgis, M. (2021). Diabetes and COVID-19: Population impact 18 months into the pandemic. *Diabetes Care, 44*(9), 1916–1923. https://care.diabetesjournals.org/content/44/9/1916

- Holman, N., Knighton, P., Kar, P., et al. (2020). Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. *The Lancet Diabetes & Endocrinology, 8*(10), 823–833. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(20)30271-0/fulltext

- Sallé, A. (2018). Diabetes: a factor of malnutrition. *Nutrition Clinique et Métabolisme, 32*(1), 8-21. https://www.sciencedirect.com/science/article/pii/S0985056217301942

- Moore, A. F., Abourizk, N., & Collins, J. (2008). Diabetic emergencies in the urgent care setting. *Journal of Urgent Care Medicine*. https://www.jucm.com/diabetic-emergencies-in-the-urgent-care-setting/

- Diabetes UK. (2021, February 18). *UK Government announces 1.7 million extra people in England asked to shield*. Diabetes UK. https://www.diabetes.org.uk/about_us/news/1-7-million-extra-people-in-england-asked-to-shield

---

*Note: All URLs are hyperlinked in the references above for direct access.*